Contrast Enhanced Spectral Mammography (CESM) Indications

Main Article Content

Wilaiporn Bhothisuwan, MD
Pramaporn Kimhamanon, RT

Abstract

Contrast enhanced spectral mammography (CESM), is a dual energy contrast enhanced digital subtraction mammography.  This technique uses the same principle as MRI of the breast, but CESM uses digital mammography instead of magnetic resonance in MRI. It provides dual energy acquisitions through low and high energies in different filters. The subtraction is obtained by emitting a different energy after a complete non-ionic contrast  media injection after 2 minutes with breast compression and  preprogrammed software without motion artifact. The benefits  include better resolution, and ability to evaluate microcalcifications,  it is more cost-effective, easier to administer with a shorter time of examination.

Article Details

How to Cite
1.
Bhothisuwan W, Kimhamanon P. Contrast Enhanced Spectral Mammography (CESM) Indications. BKK Med J [Internet]. 2014 Sep. 20 [cited 2024 Dec. 22];8(1):94. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/220202
Section
Speacial Feature

References

1. Macura KJ1, Ouwerkerk R, Jacobs MA, et al. Patterns of enhancement on breast MR images: interpretation and imaging pitfalls. Radiographics 2006;26:1719-34.
2. BluemkeDA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292:2735-42.
3. Moy L, Elias K, Patel V, et al. Is breast MRI helpful in the evaluation of inconclusive mammographic findings? AJR Am J Roentgenol 2009; 193:986-93.
4. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004;233:830-49.
5. Bedrosian I, Mick R, Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003; 98:468-73.
6. Liberman L, Morris EA, Dershaw DD, et al. MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol 2003;180:901-10.
7. Schelfout K, Van Goethem M, Kersschot E, et al. Contrast-enhanced MRI imaging of breast lesions and effect on treatment. Eur J Surg Oncol 2004;30:501-7.
8. Schnall MD, Blume J, Bluemke DA, et al. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol 2005;92:32-8.
9. VanGoethem M, Schelfout K, Kersschot E, et al. Enhancing area surrounding breast carcinoma on MR mammography: Comparison with pathological examination. Eur Radiol 2004;14:1363-70.
10. Boetes C, Mus RD, Holland R, et al. Breast tumors: Comparative accuracy of MR imaging relative to mammography and US for demonstrating extent. Radiology 1995;197:743-7.
11. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295-1303.
12. Lee SG, Orel SG, Woo IJ, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: Preliminary results. Radiology 2003; 226:773-8.
13. Liberman L, Morris EA, Kim CM, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. AJR Am J Roentgenol 2003; 180:333-41.
14. Berg WA. Imaging the local extent of disease. Semin Breast Dis 2001;4:153-73.
15. Hwang ES, Kinkel K, Esserman LI, et al. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: Value in the diagnosis of residual disease, occult invasion and multicentricity. Ann Surg Oncol 2003;10:381-8.
16. Kreche KN, Gisvold JJ. Invasive lobular carcinoma of the breast: Mammographic findings and extent of disease at diagnosis in 184 patients. AJR Am J Roentgenol 1993; 161:957-60.
17. Dillon MF, Hill AD, Fleming FJ, et al. Identifying patients at risk of compromised margins following breast conservation for lobular carcinoma. Am J Surg 2006; 191:201-5.
18. Mann RM, Hoogeveeri YL, Blickman JG, et al. MRI compared to conventional diagnostic work-up in the detection and evaluation of invasive lobular carcinoma of the breast: A review of existing literature. Breast Cancer Res Treat 2008;107:1-14.
19. Rodenko GN, Harris SE, Prurieda JM, et al. MR imaging in the management before surgery of lobular carcinoma of the breast: Correlation with pathology. AJR Am J Roentgenol 1996;167:1415-9.
20. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89.
21. Orel SG, Weinstein SP, Schnall MD, et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology 1999;212:543-9.
22. Buchanan CL, Morris EA, Doru PL, et al. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Amer Surg Oncol 2005; 12:1045-53.
23. Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003;181:619-26.
24. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233-41.
25. Orel SG, Reynolds C, Schnall MD, et al. Breast carcinoma MR imaging before re-excisional biopsy. Radiology 1997:205;429-39.
26. Frei KA, Kinkel K, Bonel HM, et al. MR imaging of the breast in patients with positive margins after lumpectomy: Influence of the time interval between lumpectomy and MR imaging. AJR Am J Roentgenol 2000;175:1577-84.
27. Lee JM, Orel SG, Czerniecki BJ, et al. MRI before re-excision surgery in patients with breast cancer. AJR Am J Roentgenol 2004;182:473-80.
28. Yeh E, Slanetz P, Kopans D, et al. Prospective comparison of mammography, sonography and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 2005:184;868-77.
29. S, Gibbs J, Yin L, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 2002;179:1193-9.
30. Belli P, Consantini M, Malaspina C, et al. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol 2006;61:946-53.
31. Rosen EL, Blackwell KL, Baker JA, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003; 181:1275-82.
32. Helvie MA, Bailey JE, Roubidoux MA, et al. Mam-mographic screening of TRAM flap breast reconstructions for detection of non palpable recurrent cancer. Radiology 2002;224:211-6.